Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Relay Therapeutics Inc RLAY

Healthcare Biotechnology
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:RLAY)

Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025

GlobeNewswire 3 days ago

Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates

GlobeNewswire November 6, 2025

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November

GlobeNewswire November 3, 2025

Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025

GlobeNewswire October 30, 2025

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

GlobeNewswire August 28, 2025

Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates

GlobeNewswire August 7, 2025

Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025

GlobeNewswire July 31, 2025

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

GlobeNewswire June 11, 2025

Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025

GlobeNewswire June 2, 2025
View More News ››

Opinion & Analysis (NDAQ:RLAY)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:RLAY)

To the Moon!

https://discord.gg/P4fHqHzkcN
Gamaliel - August 9, 2021

To the Moon!!!

https://discord.gg/P4fHqHzkcN
Gamaliel - August 9, 2021
View more Bullboard ››

AJA Health and Wellness Inc

AJA Health and Wellness Inc

AJA Health and Wellness Inc. operates a telemedicine platform and full-service travel clinics. The company offers virtual ...
View More »